Eli Lilly Submits Orforglipron for Obesity Treatment Approval and Expands Access to Obesity Medicines

Eli Lilly's proxy statement highlights the submission of orforglipron, an oral GLP-1 therapy, for obesity treatment approval in the U.S. and Japan, and for obesity and type 2 diabetes in the EU. The company also announced a landmark agreement with the U.S. government to broaden access to obesity medicines, aiming to reduce out-of-pocket costs for millions of Americans.